Pharmacology of Ampakine Modulators: From AMPA Receptors to Synapses and Behavior
The DOI matches its Crossref record.
Abstract
Ampakines are drugs structurally derived from aniracetam that potentiate currents mediated by AMPA type glutamate receptors. These drugs slow deactivation and attenuate desensitization of AMPA receptor currents, increase synaptic responses and enhance long-term potentiation. This review focuses mainly on recent physiological studies and on evidence for two distinct subfamilies. Type I compounds like CX546 are very effective in prolonging synaptic responses while type II compounds like CX516 mainly increase response amplitude. Type I and II drugs do not compete in binding assays and thus presumably act through separate sites. Their differences are likely to have consequences also for synaptic plasticity and behavior. Thus, while all ampakines facilitated long-term potentiation, only CX546 enhanced long-term depression. Further discussed are studies showing that ampakine effects vary substantially between neurons, with increases in EPSCs being larger in CA1 pyramidal cells than in thalamus and in hippocampal interneurons. In behavioral tests, ampakines facilitate learning in many paradigms including odor discrimination, spatial mazes, and conditioning, and they improved short-term memory in a non-matching-to-sample task. Positive results were also obtained in various psychological tests with human subjects. The drugs were effective in correcting behaviors in various animal models of schizophrenia and depression. Lastly, evidence is discussed that ampakines have few adverse effects at therapeutically relevant concentrations and that they protect neurons against neurotoxic insults, in part by mobilizing growth factors like BDNF. Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
“These include agents that stimulate AMPA-type glutamate receptors or ‘AMPAkines’ (Arai and Kessler, 2007), although studies to date have not shown efficacy for either symptoms or cognition (Goff et al, 2008).”
BackgroundStructure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Signaling pathways underlying the rapid antidepressant actions of ketamine
Duman, R. S., Li, N., Liu, R.-J., Duric, V., & Aghajanian, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.044 · Cited by 537
“Positive AMPA receptormodulating agents have the ability to enhance AMPA receptor function without direct receptor activation (Arai and Kessler, 2007).”
Duman, R. S., & Li, N. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0357 · Cited by 362
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Cognitive Training in Mental Disorders: Update and Future Directions
Keshavan, M. S., Vinogradov, S., Rumsey, J., Sherrill, J., & Wagner, A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13081075 · Cited by 318
Neuroplasticity Underlying the Comorbidity of Pain and Depression
Doan, L., Manders, T., & Wang, J. (2015) · Neural Plasticity · doi:10.1155/2015/504691 · Cited by 282
Clarkson, A. N., Overman, J. J., Zhong, S., Mueller, R., Lynch, G., & Carmichael, S. T. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5780-10.2011 · Cited by 276
“These are termed high-impact, or type II, ampakines (Arai and Kessler, 2007).”
BackgroundDuman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
Jourdi, H., Hsu, Y.-T., Zhou, M., Qin, Q., Bi, X., & Baudry, M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6078-08.2009 · Cited by 226
“Positive AMPA receptor modulators (PARMs, also known as ampakines) are allosteric ligands that increase glutamatemediated responses of AMPA receptors by modifying the kinetics of the receptors (activation, deactivation, desensitization) (Arai and Kessler, 2007).”
BackgroundSynaptic evidence for the efficacy of spaced learning
Kramár, E. A., Babayan, A. H., Gavin, C. F., Cox, C. D., Jafari, M., Gall, C. M., Rumbaugh, G., & Lynch, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120700109 · Cited by 192
“We tested this using a positive allosteric modulator of AMPA-type glutamate receptors (18, 19) to increase the composite depolarization produced by TBS1 (Fig.”
MethodAMPA receptors as drug targets in neurological disease—advantages, caveats, and future outlook
Chang, P. K. ‐., Verbich, D., & McKinney, R. A. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08165.x · Cited by 155
Pallas‐Bazarra, N., Jurado‐Arjona, J., Navarrete, M., Esteban, J. A., Hernández, F., Ávila, J., & Llorens‐Martín, M. (2016) · The EMBO Journal · doi:10.15252/embj.201593518 · Cited by 101
“Given the growing relevance of AMPA receptor-modulating compounds (known as AMPAkines) in the treatment of major depression (Bai et al , 2003; Arai & Kessler, 2007), we addressed whether the reduction in AMPA receptor expression caused by acute stress occurs in both genotypes in the same manner.”
Lynch, G., Kramár, E. A., Babayan, A. H., Rumbaugh, G., & Gall, C. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.006 · Cited by 97
Schmidt, M. V., Trümbach, D., Weber, P., Wagner, K., Scharf, S. H., Liebl, C., Datson, N., Namendorf, C., Gerlach, T., Kühne, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4668-10.2010 · Cited by 91
“These drugs potentiate AMPA-mediated currents by slowing receptor deactivation and attenuating receptor desensitization (Arai and Kessler, 2007).”
BackgroundKadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.027 · Cited by 62
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
“Low-impact modulators, such as CX516 and CX717, were reported to be inherently safe (Arai and Kessler, 2007) probably due to deactivation-biased limited activation of AMPA-R.”
BackgroundCao, G., & Harris, K. M. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00297.2014 · Cited by 41
Targeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Pathological Synaptic Plasticity in Neurological Disorders
Jin, C., & Karlstedt, K. (2025) · Synaptic Plasticity - Neurobiology, Neuroanatomy, and Clinical Neuroscience · doi:10.5772/intechopen.1007753 · Cited by 1
Metadata
- Authors
- Arai, A., & Kessler, M.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-05-01
- Volume
- 8
- Issue
- 5
- Pages
- 583-602
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2065521724
- Cited by
- 211
- References
- 0
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.